Androgenic alopeciahttps://en.wikipedia.org/wiki/Pattern_hair_loss
Androgenic alopecia kurasikirwa kwebvudzi kunonyanya kukanganisa kumusoro uye mberi kwemusoro. Mukurasikirwa kwebvudzi remurume (MPHL), kurasikirwa kwebvudzi kunowanzo kuzviratidza senge iri kucheuka mutsara wekumberi, kurasikirwa kwebvudzi pamucheto wemusoro, kana musanganiswa wezvose. Kurasika kwebvudzi rechikadzi (FPHL) kunowanzo ratidza sekutetepa kwakapararira kwebvudzi mumusoro mese.

Kurasika kwebvudzi remurume kunoratidzika kunge kunokonzerwa nekubatanidzwa kwemajini uye kutenderera androgens, kunyanya dihydrotestosterone (DHT). Chikonzero chekurasikirwa kwebvudzi kwevakadzi chinoramba chisina kujeka.

Mishonga yakajairika inosanganisira minoxidil, finasteride, dutasteride, kana kuvhiyiwa kwebvudzi. Kushandiswa kwefinasteride uye dutasteride muvakadzi vane pamuviri kunogona kukonzera hurema hwekuzvarwa.

○ Kurapwa
Finasteride uye dutasteride zvinonyanya kushanda kune varume nevakadzi postmenopausal. Low-dose oral minoxidil inogona kushandiswa kune vashoma vanosarudza makesi.
#Finasteride
#Dutasteride

○ Kurapa ― OTC Zvinodhaka
Munyika zhinji, topical minoxidil inowanikwa pane-the-counter. Kune mamwe ma‑supplements anoti anoshanda kurwisa kurasikirwa nebvudzi, asi mazhinji haana kuratidzwa nesainzi kuti anoshanda.
#5% minoxidil
☆ AI Dermatology — Free Service
Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
  • Male-pattern hair loss (kurasika kwebvudzi kwevarume)
    References Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics 34741573 
    NIH
    Although topical minoxidil, oral finasteride, and low‐level light therapy are the only FDA‐approved therapies to treat AGA, they are just a fraction of the treatment options available, including other oral and topical modalities, hormonal therapies, nutraceuticals, PRP and exosome treatments, and hair transplantation.